Cardiogen: A Research Overview of the AEDR Cardiac Bioregulator

Cardiogen belongs to a category that calls for more caution than most. It is one of the “Khavinson bioregulators” — a family of ultra-short peptides developed over decades by a single Russian research program. That origin shapes everything about how its evidence should be read: the literature is real but narrow, largely preclinical, and produced mostly by one group, with little independent replication. An honest overview has to foreground that rather than bury it.

This summary describes what the published literature reports about Cardiogen’s identity, its proposed mechanism, and the nature and limits of its evidence base. It describes findings as they appeared in their experimental systems. It is not dosing guidance, medical advice, or a recommendation for use.

What Cardiogen Is

Cardiogen is a synthetic tetrapeptide — four amino acids — with the sequence alanine-glutamic acid-aspartic acid-arginine, abbreviated AEDR. Its systematic form is H-Ala-Glu-Asp-Arg-OH, and it is cataloged in the public chemical database PubChem (CID 11583989). A point of housekeeping worth noting, because online sources are inconsistent: some pages list the sequence as ending in proline (AEDP) rather than arginine. The authoritative references — the PubChem entry and the originating patent for the compound — specify arginine, Ala-Glu-Asp-Arg (originating patent, USPTO: tetrapeptide Ala-Glu-Asp-Arg for myocardium function).

It was developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as part of a broader program that sought to isolate short peptide sequences from specific animal tissues and synthesize them as tissue-targeted “bioregulators.” Cardiogen came from the cardiac-tissue arm of that program.

Proposed Mechanism

The proposed mechanism is what makes the Khavinson peptides distinctive — and also what makes them unusual claims to evaluate. While most cardiovascular research compounds act on cell-surface receptors (adrenoceptors, angiotensin receptors, and so on), Cardiogen is proposed to act differently: enter the cell, reach the nucleus, and interact directly with DNA or chromatin to influence which genes are transcribed. In other words, it is described as an epigenetic-style regulator rather than a receptor agonist.

In cell-culture work from the originating program, exposure to the AEDR peptide was reported to increase expression of cytoskeletal proteins (actin, tubulin, vimentin) and nuclear-matrix proteins (lamin A and C) in cultured fibroblasts, and to suppress markers of apoptosis — changes the authors interpreted as evidence of a cell-protective, anti-apoptotic action (Chalisova et al., myocardial tissue-culture study (PubMed)). It is important to read these as proposed and preliminary mechanistic observations in cultured cells. The direct-DNA-binding model for this peptide family is a hypothesis advanced largely within the originating program and is not widely established in the broader molecular biology literature.

The Evidence Base — Narrow and Preclinical

This is the section that matters most for Cardiogen, because the gap between how it is marketed and what has actually been shown is wide.

Essentially all of the published research is in vitro (cultured cells) or in animals, and the great majority originates from the Khavinson group and its collaborators. Indexed examples exist — for instance, a 2009 study on a tumor-modifying effect of Cardiogen in aged rats appears in PubMed (Levdik & Knyazkin, 2009, PubMed) — but they are small, mechanistic, and concentrated in a narrow set of journals. Independent replication by unaffiliated laboratories is sparse, and the body of work has not been synthesized into a large, multi-group evidence base that would support confident conclusions.

Most importantly, there are no controlled human clinical trials establishing efficacy for any cardiac indication. Phrases like “cardiac repair” or “cardiovascular anti-aging” that circulate in product copy describe hypotheses and preclinical observations, not demonstrated outcomes in people. The honest characterization is that Cardiogen is an interesting but lightly evidenced research compound whose central claims rest heavily on a single program’s work.

• The findings described here come from cultured cells and animal studies, overwhelmingly from a single research program.
• Independent, third-party replication of the key mechanistic claims is limited.
• No controlled human clinical trials have established efficacy for any indication.

Regulatory Status

The status below reflects mid-2026 and may change; verify against current sources before relying on it. Cardiogen is not FDA-approved for any indication in the United States. Its situation differs from the peptides tied up in the FDA’s 503A compounding review: Cardiogen is generally registered in Russia within a biologically-active-additive category (broadly comparable to a supplement classification there) and is sold over the counter in that market, while in Western markets it moves through research-chemical and gray-market channels (research-use status (PubMed-indexed Khavinson literature)).

Two cautions follow. Registration as a biologically active additive in one country is a marketing/regulatory category, not evidence of clinical efficacy or a U.S. approval. And research-grade material sold for laboratory use is, by its own labeling, not intended for human or veterinary use — a designation that carries both legal and quality-control weight, since such material is not held to pharmaceutical manufacturing standards.

Why Cardiogen Appears in Research Discussions

The interest is conceptual. Cardiogen sits within a genuinely distinctive research idea — that ultra-short, tissue-derived peptides might act as gene-level regulators of the tissues they came from — and it is the cardiac member of that family. For researchers curious about that hypothesis, it is a defined, low-molecular-weight tool compound. The accurate framing, though, is that it is the subject of an intriguing but narrow, largely single-source research program with no clinical validation, rather than an established cardioprotective agent. Curiosity is warranted; confidence is not.

For deeper reading, the primary literature cited throughout this article is the best starting point. Related short-peptide and bioregulator topics are collected in our peptide research library, which gathers reference material on the wider class of compounds discussed here.

A note on the evidence base: Independent, peer-reviewed evidence in English is limited; much of the available literature on Cardiogen originates from the originating research group (the Khavinson program) and has not been widely replicated. The citations below reflect that literature, and readers should weigh it accordingly.